triazoles has been researched along with Aplasia Pure Red Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, K; Kojima, M; Machida, S; Miyamoto, M; Moriuchi, M; Ohbayashi, Y; Sato, A | 1 |
| Hayakawa, F; Naoe, T; Tomita, A | 1 |
2 other study(ies) available for triazoles and Aplasia Pure Red Cell
| Article | Year |
|---|---|
Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.
Topics: Benzoates; Deferasirox; Erythrocyte Transfusion; Erythropoiesis; Female; Humans; Iron Chelating Agents; Middle Aged; Red-Cell Aplasia, Pure; Treatment Outcome; Triazoles | 2013 |
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Triazoles | 2014 |